A structural powder diffraction study of two polymorphic forms of nortriptyline hydrochloride

Journal of Pharmaceutical Sciences

Volumn 101, Issue 12, 2012, Pages 4481-4489

  Vladiskovic, Chiara ^a,b   Masciocchi, Norberto ^b   Cervellino, Antonio ^c  

^a Dipharma Francis srl   (Italy)

^b UNIVERSITY OF INSUBRIA   (Italy)

^c PAUL SCHERRER INSTITUTE   (Switzerland)

Author keywords

Calorimetry (DSC); Crystal structure; Crystallography; Polymorphism; Solid state; Thermal analysis; X ray powder diffractometry

Indexed keywords

EID: 84868200301     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23310     Document Type: Article

References (23)

1. Brittain H, Ed. 2009. Polymorphism in pharmaceutical solids. New York: Informa Healthcare USA, Inc.
2. Hilfiker R, Ed. 2006. Polymorphism in the pharmaceutical industry. Weinheim, Germany: Wiley VCH.
3. U'Prichard DC, Greenberg DA, Sheehan PP, Snyder SH. 1978. Tricyclic antidepressants: Therapeutic properties and affinity for alpha-noradrenergic binding sites in the brain. Science 199(4325):197-198.
4. European Pharmacopoeia, Monograph Number 01/2010:0941 2011.
5. US Pharmacopeia, USP 35:4087-4088. 2011.
6. MacCalman ML, Roberts KJ, Hendriksen BA. 1993. The influence of growth environment on the crystallization of nortryptiline hydrochloride, a tricyclic antidepressant. J Crystal Growth 128:1218-1224.
7. Klein CL, Banks TA, Rouselle D. 1991. Structure of nortryptiline hydrochloride. Acta Crystallogr C47:1478-1480.
8. Halasz I, Dinnebier RE. 2009. Structural and thermal characterization of zolpidem hemitartrate hemidydrate (Form E) and its decomposition products by laboratory X-ray powder diffraction. J Pharm Sci 99:871-878.
9. Ferreira FF, Gutierrez Antonio S, Pires Rosa PC, De Oliveira Paiva-Santos C. 2009. Crystal structure determination of mebendazole form a using high-resolution synchrotron X-ray powder diffraction data. J Pharm Sci 99:1734-1744.
10. Amidon GL, Lennernas H, Shah VP, Crison JR. 1995. A theoretical basis for a Biopharmaceutic Drug Classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm Res 12:413-420.
11. Yu LW, Amidon GL, Polli JE, Zhao H, Mehta MU, Conner DP, Shah VP, Lesko LJ, Chen ML, Lee VH, Hussain AS. 2002. Biopharmaceutics Classification System: The scientific basis for biowaiver extensions. Pharm Res 19:921-925.
12. Coelho AA. 2005. TOPAS-R, v3.0. Karlruhe, Germany: Bruker AXS.
13. Le Bail A, Duroy H, Fourquet JL. 1988. Ab initio structure determination of LiSbWO6 by X-ray powder diffraction. Mater Res Bull 23:447-452.
14. Klein CL, Lear J, O'Rourke S, Williams S, Liang L. 1994. Crystal and molecular structures of tricyclic neuroleptics. J Pharm Sci 83:1253-1256.
15. Siddedowda MS, Jasinski JP, Golen JA, Yathirajan HS, Swamy MT. 2011. Cyclobenzaprinium chloride. Acta Crystallogr E67:1846.
16. Bandoli G, Nicolini M, Casellato U. 1987. Cyrstal structure of two tricylic antidepressant drugs: Lofepramine hydrochloride and dothiepin hydrochloride. J Chem Crystallogr 17:281-293.
17. Ohshima E, Otaki S, Sato K, Kumazawa T, Obase H, Ishii A, Ishii H, Ohmori K, Hirayama N. 1992. Synthesis and antiallergic activity of 11-(aminoalkylidene)-6, 11-dihydrobenz[b, e]oxepin derivatives. J Med Chem 35:2074-2084.
18. Marone S, Rozas I, Weaver DF. 1999. Theoretical structural analyses of tricyclic neuroactive drugs: Quantum pharmacologic descriptors for clustering anticonvulsant, antidepressant, and antipsychotic activities. J Mol Struct 467:25-30.
19. Munro S, Craik DJ, Andrews P. 1987. Conformational analysis of flexible antidepressant drugs. QSAR 6:104-110.
20. Casarotto MG, Craik J. 2001. Ring flexibility within tricyclic antidepressant drugs. J Pharm Sci 90:713-721.
21. Jablan SV. 1995. Theory of symmetry and ornament. Belgrade, Yugoslavia: Mathematical Institute.
22. Eufri D, Sironi A. 1989. SMILE-Shaded molecular imaging on low-cost equipment. J Mol Graph 7(3):165-169.
23. Stinton GW, Evans JSO. 2007. Parametic Rietveld refinements. J Appl Crystallogr 40:87-95.